The latest update is out from HUTCHMED (China) Limited ( (HK:0013) ).
HUTCHMED has completed patient enrollment for a Phase II registration study of savolitinib in gastric cancer patients with MET amplification in China. The study aims to evaluate the efficacy, safety, and tolerability of savolitinib, with interim results showing promising response rates. The drug has received Breakthrough Therapy Designation from China’s National Medical Products Administration, and if successful, HUTCHMED plans to seek marketing authorization in China by late 2025. This development could enhance HUTCHMED’s position in the oncology market, potentially offering a new treatment option for patients with MET-driven gastric cancer, which currently has a poor prognosis.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought several drug candidates from in-house discovery to the market, with its first three medicines marketed in China and one approved globally, including in the US, Europe, and Japan.
YTD Price Performance: -9.79%
Average Trading Volume: 50,983
Technical Sentiment Signal: Buy
Current Market Cap: £1.87B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.